Shape Pharmaceuticals Provides Update on SHP-141 Topical HDAC Inhibitor Clinical Development for Cutaneous T Cell Lymphoma
3/4/2013 9:58:27 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shape Pharmaceuticals today provided an update on the clinical development of SHP-141, its novel, topically administered histone deacetylase inhibitor (HDACi) for the treatment of cutaneous T cell lymphoma (CTCL). SHP-141 is currently undergoing a multi-center, randomized, placebo-controlled Phase 1b clinical trial to evaluate the safety and tolerability of the compound at escalating doses in patients with Stage 1A, 1B or 2A CTCL. The trial is also evaluating the effect of the compound on skin lesions in these patients. Two of the study’s three dose escalating cohorts have been treated, and the study is proceeding on track.
comments powered by